Merus Yönetim

Yönetim kriter kontrolleri 4/4

Merus CEO'su Bill Lundberg, Dec2019 tarihinde atandı, in görev süresi 4.92 yıldır. in toplam yıllık tazminatı $ 4.67M olup, şirket hissesi ve opsiyonları dahil olmak üzere 13.9% maaş ve 86.1% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.22% ine doğrudan sahiptir ve bu hisseler $ 6.53M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.8 yıl ve 6.3 yıldır.

Anahtar bilgiler

Bill Lundberg

İcra Kurulu Başkanı

US$4.7m

Toplam tazminat

CEO maaş yüzdesi	13.9%
CEO görev süresi	4.9yrs
CEO sahipliği	0.2%
Yönetim ortalama görev süresi	2.8yrs
Yönetim Kurulu ortalama görev süresi	6.3yrs

Son yönetim güncellemeleri

Recent updates

Merus: Petosemtamab Set Up For December 2024 Data Presentation

Nov 05

We're Hopeful That Merus (NASDAQ:MRUS) Will Use Its Cash Wisely

Sep 20

Merus N.V.'s Innovative Cancer Therapies: Balancing Its IP Potential With Financial Risks

Aug 14

Analysts Just Made A Major Revision To Their Merus N.V. (NASDAQ:MRUS) Revenue Forecasts

Jun 01

Merus Stock: Priced High After An ASCO Surprise Surge (Maintain Buy)

May 24

Earnings Beat: Merus N.V. (NASDAQ:MRUS) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

May 12

Risks To Shareholder Returns Are Elevated At These Prices For Merus N.V. (NASDAQ:MRUS)

Dec 18

We Think Merus (NASDAQ:MRUS) Needs To Drive Business Growth Carefully

Sep 19

Merus N.V.'s (NASDAQ:MRUS) Business Is Yet to Catch Up With Its Share Price

Jun 20

Is Merus (NASDAQ:MRUS) In A Good Position To Invest In Growth?

May 24

Merus N.V. (NASDAQ:MRUS) Shares Could Be 26% Below Their Intrinsic Value Estimate

Feb 08

Merus GAAP EPS of -$0.13 beats by $0.49, revenue of $12.68M beats by $2.23M

Aug 08

Merus N.V. initiated with Buy at Stifel based on three bispecific antibodies

Aug 02

Merus: Precision Oncology Pioneer Continues To Execute In The Clinic

Jun 30

Need To Know: Analysts Are Much More Bullish On Merus N.V. (NASDAQ:MRUS)

May 14

Merus (NASDAQ:MRUS) Is In A Strong Position To Grow Its Business

Apr 25

New Forecasts: Here's What Analysts Think The Future Holds For Merus N.V. (NASDAQ:MRUS)

Mar 03

We're Not Worried About Merus' (NASDAQ:MRUS) Cash Burn

Nov 25

News Flash: Analysts Just Made A Sizeable Upgrade To Their Merus N.V. (NASDAQ:MRUS) Forecasts

Aug 08

Calculating The Intrinsic Value Of Merus N.V. (NASDAQ:MRUS)

Jul 28

We're Not Very Worried About Merus' (NASDAQ:MRUS) Cash Burn Rate

Jul 02

CEO Tazminat Analizi

Bill Lundberg'un ücretlendirmesi Merus'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-US$245m
Jun 30 2024	n/a	n/a	-US$168m
Mar 31 2024	n/a	n/a	-US$150m
Dec 31 2023	US$5m	US$650k	-US$155m
Sep 30 2023	n/a	n/a	-US$177m
Jun 30 2023	n/a	n/a	-US$178m
Mar 31 2023	n/a	n/a	-US$152m
Dec 31 2022	US$6m	US$599k	-US$131m
Sep 30 2022	n/a	n/a	-US$64m
Jun 30 2022	n/a	n/a	-US$54m
Mar 31 2022	n/a	n/a	-US$76m
Dec 31 2021	US$8m	US$582k	-US$67m
Sep 30 2021	n/a	n/a	-US$80m
Jun 30 2021	n/a	n/a	-US$89m
Mar 31 2021	n/a	n/a	-US$79m
Dec 31 2020	US$5m	US$565k	-US$86m
Sep 30 2020	n/a	n/a	-US$83m
Jun 30 2020	n/a	n/a	-US$69m
Mar 31 2020	n/a	n/a	-US$65m
Dec 31 2019	US$162k	n/a	-US$55m

Tazminat ve Piyasa: Bill 'ın toplam tazminatı ($USD 4.67M ) US pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 6.60M ).

Tazminat ve Kazançlar: Bill 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Bill Lundberg (61 yo)

4.9yrs

Görev süresi

US$4,671,327

Tazminat

Dr. Sven Ante Lundberg, also known as Bill, M.D. is Venture Advisor of Forge Life Science Partners. He serves as Chief Executive Officer, President and Executive Director of Merus N.V. since December 31, 2...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Sven Lundberg	CEO, President & Executive Director	4.9yrs	US$4.67m	0.22% $ 6.5m
Gregory Perry	Chief Financial Officer	1.4yrs	US$6.21m	0% $ 0
Peter Silverman	EVP, Company Secretary	6.8yrs	US$1.95m	Veri yok
Hennie Hoogenboom	Co-Founder and Scientific Advisor	no data	Veri yok	Veri yok
Harry Shuman	Chief Accounting Officer	no data	Veri yok	0.010% $ 300.7k
Cornelis de Kruif	CTO & Executive VP	11.8yrs	US$609.22k	Veri yok
Cecilia Anna Geuijen	Chief Scientific Officer & Senior VP	3.5yrs	Veri yok	Veri yok
Kathleen Farren	IR & Corporate Communications Officer	no data	Veri yok	Veri yok
Audrey Bergan	Chief People Officer	no data	Veri yok	Veri yok
Shannon Campbell	Executive VP & Chief Commercial Officer	2.8yrs	Veri yok	Veri yok
Ashley Pereira	Senior Vice President of Regulatory Affairs	2.8yrs	Veri yok	Veri yok
Ernesto Wasserman	Senior Vice President of Clinical Development	2.8yrs	Veri yok	Veri yok

2.8yrs

Ortalama Görev Süresi

59yo

Ortalama Yaş

Deneyimli Yönetim: MRUS 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.8 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Sven Lundberg	CEO, President & Executive Director	5.4yrs	US$4.67m	0.22% $ 6.5m
Elaine Jones	Board Observer	14.8yrs	Veri yok	Veri yok
Maxine Gowen	Independent Non-Executive Director	3.5yrs	US$305.06k	0% $ 0
Anand Mehra	Independent Chairman	9.3yrs	US$417.56k	0% $ 0
Paolo Pucci	Independent Non-Executive Director	4.4yrs	US$309.56k	0% $ 0
Mark Iwicki	Independent Non Executive Director	9.4yrs	US$311.06k	0.11% $ 3.2m
Antoni Ribas	Member of Scientific Advisory Board	6.3yrs	Veri yok	Veri yok
Victor Sandor	Independent Non-Executive Director	5.4yrs	US$303.56k	0% $ 0
Josep Tabernero Caturla	Member of Scientific Advisory Board	6.3yrs	Veri yok	Veri yok
Antonius Schumacher	Member of Scientific Advisory Board	6.3yrs	Veri yok	Veri yok
Jason Haddock	Independent Non-Executive Director	less than a year	Veri yok	Veri yok
Len Kanavy	Independent Non-Executive Director	6.3yrs	US$303.56k	0% $ 0

6.3yrs

Ortalama Görev Süresi

59.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: MRUS 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 6.3 yıldır).

Merus Yönetim

Yönetim kriter kontrolleri 4/4

Anahtar bilgiler

Son yönetim güncellemeleri

Merus N.V. Announces Chief Medical Officer Changes

Merus N.V. Appoints Jason Haddock as Non-Executive Director

Merus N.V., Annual General Meeting, May 07, 2024

EVP, Company Secretary notifies of intention to sell stock

Merus Appoints Greg Perry as Chief Financial Officer

Independent Non Executive Director exercised options to buy US$1.5m worth of stock.

Recent updates

Merus: Petosemtamab Set Up For December 2024 Data Presentation

Merus N.V. Announces First Patient Dosed in Liger-Hn1, A Phase 3 Trial Evaluating Petosemtamab in Combination with Pembrolizumab in 1L R/M HNSCC

We're Hopeful That Merus (NASDAQ:MRUS) Will Use Its Cash Wisely

Merus N.V.'s Innovative Cancer Therapies: Balancing Its IP Potential With Financial Risks

Merus N.V. Announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 2L CRC

Merus N.V. Announces Chief Medical Officer Changes

Merus N.V. Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab At the 2024 ASCO® Annual Meeting

Analysts Just Made A Major Revision To Their Merus N.V. (NASDAQ:MRUS) Revenue Forecasts

Merus N.V. has completed a Follow-on Equity Offering in the amount of $400.15 million.

Merus N.V. has filed a Follow-on Equity Offering in the amount of $300 million.

Price target increased by 21% to US$73.36

Merus Stock: Priced High After An ASCO Surprise Surge (Maintain Buy)

Consensus revenue estimates increase by 26%

Merus N.V. Announces Petosemtamab Grants Breakthrough Therapy Designation by the U.S. FDA

Earnings Beat: Merus N.V. (NASDAQ:MRUS) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Merus (NASDAQ:MRUS) Is In A Good Position To Deliver On Growth Plans

First quarter 2024 earnings released: US$0.59 loss per share (vs US$0.86 loss in 1Q 2023)

Merus N.V. Appoints Jason Haddock as Non-Executive Director

Merus N.V., Annual General Meeting, May 07, 2024

Price target increased by 7.6% to US$59.18

Merus N.V. announced that it has received $25.000035 million in funding from Gilead Sciences, Inc.

Full year 2023 earnings: EPS and revenues miss analyst expectations

Merus: Positive Zenocutuzumab Data In 2024 Could Provide BLA Advancement

Price target increased by 16% to US$51.60

Merus N.V. has filed a Follow-on Equity Offering in the amount of $300 million.

Merus N.V.'s (NASDAQ:MRUS) Shares Climb 30% But Its Business Is Yet to Catch Up

Merus Stock: Rally Seems Overdone

Are Investors Undervaluing Merus N.V. (NASDAQ:MRUS) By 45%?

Risks To Shareholder Returns Are Elevated At These Prices For Merus N.V. (NASDAQ:MRUS)

EVP, Company Secretary notifies of intention to sell stock

Consensus EPS estimates upgraded to US$2.60 loss

Consensus estimates of losses per share improve by 12%

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Merus N.V. Announces Interim Data Continues to Demonstrate Robust and Durable Responses in NRG1+ Cancer

New major risk - Revenue and earnings growth

We Think Merus (NASDAQ:MRUS) Needs To Drive Business Growth Carefully

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

U.S. Food and Drug Administration Grants Second Breakthrough Therapy Designation for zenocutuzumab (Zeno) of Merus N.V

Merus N.V.'s (NASDAQ:MRUS) Business Is Yet to Catch Up With Its Share Price

Merus Appoints Greg Perry as Chief Financial Officer

Is Merus (NASDAQ:MRUS) In A Good Position To Invest In Growth?

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates upgraded to US$3.63 loss

Independent Non Executive Director exercised options to buy US$1.5m worth of stock.

Price target increased by 8.6% to US$40.67

Price target increased by 8.5% to US$39.67

Chief Business Officer exercised options to buy US$1.9m worth of stock.

Full year 2022 earnings released: US$2.92 loss per share (vs US$1.73 loss in FY 2021)

Now 21% undervalued

Merus N.V. (NASDAQ:MRUS) Shares Could Be 26% Below Their Intrinsic Value Estimate

Merus N.V. Announces Executive Changes

Price target decreased to US$37.11

Consensus forecasts updated

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$38.44

Merus N.V. Presents First in Human Data on MCLA-129 at the 34th EORTC/NCI/AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics

Consensus forecasts updated

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Merus GAAP EPS of -$0.13 beats by $0.49, revenue of $12.68M beats by $2.23M

Merus N.V. initiated with Buy at Stifel based on three bispecific antibodies

Merus: Precision Oncology Pioneer Continues To Execute In The Clinic

Merus N.V. Presents Clinical Data on Zenocutuzumab in NRG1-Fusion Cancer at the 2022 American Society of Clinical Oncology Annual Meeting

Consensus revenue estimates increase by 15%

Need To Know: Analysts Are Much More Bullish On Merus N.V. (NASDAQ:MRUS)

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Merus N.V., Annual General Meeting, May 31, 2022

Merus (NASDAQ:MRUS) Is In A Strong Position To Grow Its Business

Executive VP exercised options and sold US$947k worth of stock

Merus N.V. Announces Publication of Abstract on MCLA-129 At the American Association for Cancer Research 2022 Annual Meeting